2.36
-0.01
(-0.42%)
May 22 - Close
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 2.36 - 2.40 |
| 52 week | 2.35 - 6.33 |
| Open | 2.38 |
| Vol / Avg. | 61,561.00/73,932.00 |
| Mkt cap | 65.59M |
| P/E | 3.14 |
| Div/yield | 3.60 |
| EPS | 0.75 |
| Shares | 27.79M |
| Beta | 0.63 |
| Inst. own | 61% |
Events
Aug 5, 2013
Q2 2013 Maxygen, Inc. Earnings Release
May 7, 2013
Q1 2013 Maxygen, Inc. Earnings Release
Mar 15, 2013
Q4 2012 Maxygen, Inc. Earnings Release
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | -71033.34% | 68.55% |
| Operating margin | -71666.66% | 67.51% |
| EBITD margin | - | 67.69% |
| Return on average assets | -10.38% | 16.60% |
| Return on average equity | -10.77% | 16.70% |
| Employees | 6 | - |
| Carbon Disclosure Rating | - | - |
Address
Suite 616, 411 Borel Avenue
SAN MATEO, CA 94402
United States - Map
+1-650-2412292 (Phone)
+1-650-2575892 (Fax)
SAN MATEO, CA 94402
United States - Map
+1-650-2412292 (Phone)
+1-650-2575892 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
Maxygen, Inc. (Maxygen) is a biotechnology company focused on the development of its MAXY-G34 product candidate. MAXY-G34 is a pegylated, granulocyte colony stimulating factor (G-CSF), for the treatment of chemotherapy-induced neutropenia and acute radiation syndrome (ARS). On May 16, 2011, Astellas Pharma Inc. (Astellas) acquired the Company�s interests in Perseid Therapeutics LLC, the Company�s former subsidiary, which included all of the Company�s research and development operations. As a result of the transaction, the Company has reclassified the operating results of Perseid, as well as any related business activities, to discontinued operations. The Company�s wholly owned subsidiaries include Maxygen Holdings (U.S.), Inc., Maxygen ApS and Maxygen Holdings, Inc., and its majority owned subsidiary, Maxygen Holdings LLC.
Officers and directors
| Isaac Stein | Executive Independent Chairman of the Board | |
| James R. Sulat | Chief Executive Officer, Chief Financial Officer, Director | |
| John M. Borkholder | General Counsel, Secretary | |
| Louis G. Lange M.D., Ph.D. | Independent Director | |
| Kenneth B Lee Jr. | Independent Director | |
| Ernest Mario Ph.D. | Independent Director | |
| Gordon Ringold Ph.D. | Independent Director |